Abstract:270 Background: Radiotracers used in prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging have high specificity for the detection of prostate cancer (PCa), and PSMA PET/CT imaging has seen increased use in the management of localized PCa. However, the diagnostic capability of PSMA PET can be limited by intense uptake in the ureters, bladder, and urethra due to physiologic urinary excretion. Specifically, radiotracer activity in the prostatic urethra can be misinterpreted as a midline intraprostatic lesion if not carefully evaluated with morphologic imaging. This study aimed to elucidate the correlation between positive 18 F-DCFPyL activity in the midline prostate with hyperintense signal on T2-weighted MRI (T2W MRI) within the prostatic urethra as an indication of retained urine. Methods: Ninety-seven patients received both 18 F-DCFPyL PSMA PET/CT and 3 Tesla prostate MRI post-void imaging for localized, high-risk PCa. Patients with prior prostate treatment (i.e., surgery, androgen deprivation therapy, or radiotherapy) or poor prostatic urethra visualization (i.e., PCa involving the whole gland, Foley catheter in situ) were excluded, resulting in a final cohort of 84 patients. Radiotracer activity in the midline region of the prostate was prospectively evaluated by two nuclear medicine physicians during PET/CT read outs. Post-void T2W MRI scans were retrospectively evaluated for the presence of residual urine noted as hyperintensity within the prostatic urethral lumen by one genitourinary radiologist blinded to PET/CT evaluations. The corresponding prostatic urethra diameters were measured on both axial and sagittal T2W MRI. Fisher’s exact test and Mann-Whitney U tests were used to compare MRI and PET/CT findings. Results: In 84 patients, midline activity on PSMA PET imaging was documented in 16 patients (the case group), whereas the remaining 68 patients without midline activity constituted the control group. In total, 75% (12/16) and 31% (21/68) of patients in the case and control groups, respectively, had urethral hyperintensity on T2W MRI (p < .01, Fisher’s exact test). In patients with a hyperintense urethral lumen at MRI, there was a significant difference in mean prostatic urethral measurements between the case and control groups in both axial (7.25 mm vs. 2.81 mm, p < .0001, Mann Whitney U) and sagittal (12.25 mm vs. 5.43 mm, p < .0001, Mann Whitney U) planes. Conclusions: Our findings suggest that PSMA uptake within the midline of the prostate is more commonly observed in patients with a prominently visible prostatic urethra at MRI, a finding that is likely associated with the stagnation of urine containing PSMA tracer. This midline uptake may be prone to misinterpretation as a potential PCa lesion on PSMA PET/CT, and the use of post-void MRIs may be useful in reducing the likelihood of false positive interpretations of PSMA PET/CT.

An Unexpected Seminal Vesicle Pitfall in PSMA PET

Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning

Effect of urinary stagnation in the prostatic urethra on generating false-positive midline lesions on 18 F-DCFPyL PSMA PET/CT.

Incidental Finding of Spindle Cell Sarcoma on 68Ga-PSMA-11 PET/CT

Intense PSMA Uptake in Solitary Fibrous Tumor of the Seminal Vesicle

Incidental Prostate-Specific Membrane Antigen–Avid Vestibular Schwannoma Detected on 68Ga–Prostate-Specific Membrane Antigen PET/CT

Case Report: Post-traumatic splenosis and potential pitfall for PSMA-PET

Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI

Unusual Prostate-Specific Membrane Antigen (PSMA) Splenic Uptake in a Patient With Prostate Cancer

Increased Prostate-Specific Membrane Antigen Uptake in a Gallbladder Stone

Unusual Presentation of Solitary Penile Metastasis of Prostate Cancer on 68Ga-PSMA PET/CT

68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan

Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient

Unsuspected Isolated Peritoneal Metastasis of Prostate Cancer Detected with Digital F-18 PSMA PET/CT Scan

An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging

False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels

Detection of benign granular cell tumor of the breast via 18F-PSMA-PET/CT in a patient with very high-risk prostate cancer: A case report

68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma Prostate

Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up

Incidental Detection of Synchronous Benign Hepatic and Splenic Hemangiomas on 18F-PSMA PET/CT

Renal Pelvis Metastasis from Prostatic Adenocarcinoma Missed by PSMA PET: A Case Report.